9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation



A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Estimated reading time: < 1 min



Estimated Enrollment: 40

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 16-549

Study First Received: March 2, 2017

Last Updated: April 20, 2017

Estimated Primary Completion Date: September 30, 2020

Primary Outcome Measures:

Overall Response Rate|Overall Survival|Progression Free Survival|Duration of Response|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Sponsors and Collaborators:

Dana-Farber Cancer Institute|AstraZeneca

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT03075527

Was this article helpful?
Views: 42